Cargando…
Inhibition of Histone Methyltransferase, Histone Deacetylase, and β-Catenin Synergistically Enhance the Cardiac Potential of Bone Marrow Cells
Previously, we reported that treatment with the G9a histone methyltransferase inhibitor BIX01294 causes bone marrow mesenchymal stem cells (MSCs) to exhibit a cardiocompetent phenotype, as indicated by the induction of the precardiac markers Mesp1 and brachyury. Here, we report that combining the hi...
Autores principales: | Yang, Jinpu, Kaur, Keerat, Edwards, John G., Eisenberg, Carol A., Eisenberg, Leonard M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5534312/ https://www.ncbi.nlm.nih.gov/pubmed/28791052 http://dx.doi.org/10.1155/2017/3464953 |
Ejemplares similares
-
Inhibition of G9a Histone Methyltransferase Converts Bone Marrow Mesenchymal Stem Cells to Cardiac Competent Progenitors
por: Yang, Jinpu, et al.
Publicado: (2015) -
Natural Products Impacting DNA Methyltransferases and Histone Deacetylases
por: Akone, Sergi Herve, et al.
Publicado: (2020) -
Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020) -
Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
por: Yao, Ya-Li, et al.
Publicado: (2011) -
Epigenetic Regulation of Host Defense Peptide Synthesis: Synergy Between Histone Deacetylase Inhibitors and DNA/Histone Methyltransferase Inhibitors
por: Whitmore, Melanie A., et al.
Publicado: (2022)